Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Original Antigenic Sin and Respiratory Syncytial Virus Vaccines.

Tripp RA, Power UF.

Vaccines (Basel). 2019 Sep 6;7(3). pii: E107. doi: 10.3390/vaccines7030107.

2.

Airway Epithelial Derived Cytokines and Chemokines and Their Role in the Immune Response to Respiratory Syncytial Virus Infection.

Glaser L, Coulter PJ, Shields M, Touzelet O, Power UF, Broadbent L.

Pathogens. 2019 Jul 19;8(3). pii: E106. doi: 10.3390/pathogens8030106. Review.

3.

Airway surface liquid has innate antiviral activity that is reduced in cystic fibrosis.

Berkebile AR, Bartlett JA, Abou Alaiwa M, Varga SM, Power UF, McCray PB Jr.

Am J Respir Cell Mol Biol. 2019 Jun 26. doi: 10.1165/rcmb.2018-0304OC. [Epub ahead of print]

PMID:
31242392
4.

The viral protein corona directs viral pathogenesis and amyloid aggregation.

Ezzat K, Pernemalm M, Pålsson S, Roberts TC, Järver P, Dondalska A, Bestas B, Sobkowiak MJ, Levänen B, Sköld M, Thompson EA, Saher O, Kari OK, Lajunen T, Sverremark Ekström E, Nilsson C, Ishchenko Y, Malm T, Wood MJA, Power UF, Masich S, Lindén A, Sandberg JK, Lehtiö J, Spetz AL, El Andaloussi S.

Nat Commun. 2019 May 27;10(1):2331. doi: 10.1038/s41467-019-10192-2.

5.

Correction: Characterisation of morphological differences in well-differentiated nasal epithelial cell cultures from preterm and term infants at birth and one-year.

Groves HE, Guo-Parke H, Broadbent L, Shields MD, Power UF.

PLoS One. 2019 Jan 25;14(1):e0211611. doi: 10.1371/journal.pone.0211611. eCollection 2019.

6.

Characterisation of morphological differences in well-differentiated nasal epithelial cell cultures from preterm and term infants at birth and one-year.

Groves HE, Guo-Parke H, Broadbent L, Shields MD, Power UF.

PLoS One. 2018 Dec 5;13(12):e0201328. doi: 10.1371/journal.pone.0201328. eCollection 2018. Erratum in: PLoS One. 2019 Jan 25;14(1):e0211611.

7.

Pulmonary epithelial barrier and immunological functions at birth and in early life - key determinants of the development of asthma?  A description of the protocol for the Breathing Together study.

Turner S, Custovic A, Ghazal P, Grigg J, Gore M, Henderson J, Lloyd CM, Marsland B, Power UF, Roberts G, Saglani S, Schwarze J, Shields M, Bush A.

Wellcome Open Res. 2018 May 17;3:60. doi: 10.12688/wellcomeopenres.14489.1. eCollection 2018.

8.

Phylogenetic analysis of porcine reproductive and respiratory syndrome virus isolates from Northern Ireland.

Smith N, Power UF, McKillen J.

Arch Virol. 2018 Oct;163(10):2799-2804. doi: 10.1007/s00705-018-3886-7. Epub 2018 May 29.

PMID:
29845350
9.

Pro-inflammatory mediator responses from neonatal airway epithelial cells and early childhood wheeze.

Turner S, Miller D, Walsh GM, Scaife A, Power UF, Shields MD, Devereux G.

Pediatr Pulmonol. 2018 Jan;53(1):10-16. doi: 10.1002/ppul.23915. Epub 2017 Nov 14.

PMID:
29136347
10.

Respiratory Syncytial Virus: Targeting the G Protein Provides a New Approach for an Old Problem.

Tripp RA, Power UF, Openshaw PJM, Kauvar LM.

J Virol. 2018 Jan 17;92(3). pii: e01302-17. doi: 10.1128/JVI.01302-17. Print 2018 Feb 1. Review.

11.

The RNA binding protein La/SS-B promotes RIG-I-mediated type I and type III IFN responses following Sendai viral infection.

Mahony R, Broadbent L, Maier-Moore JS, Power UF, Jefferies CA.

Sci Rep. 2017 Nov 6;7(1):14537. doi: 10.1038/s41598-017-15197-9.

12.

Broad-Spectrum Inhibition of Respiratory Virus Infection by MicroRNA Mimics Targeting p38 MAPK Signaling.

McCaskill JL, Ressel S, Alber A, Redford J, Power UF, Schwarze J, Dutia BM, Buck AH.

Mol Ther Nucleic Acids. 2017 Jun 16;7:256-266. doi: 10.1016/j.omtn.2017.03.008. Epub 2017 Apr 6.

13.

Antibody-Induced Internalization of the Human Respiratory Syncytial Virus Fusion Protein.

Leemans A, De Schryver M, Van der Gucht W, Heykers A, Pintelon I, Hotard AL, Moore ML, Melero JA, McLellan JS, Graham BS, Broadbent L, Power UF, Caljon G, Cos P, Maes L, Delputte P.

J Virol. 2017 Jun 26;91(14). pii: e00184-17. doi: 10.1128/JVI.00184-17. Print 2017 Jul 15.

14.

Respiratory virus infection up-regulates TRPV1, TRPA1 and ASICS3 receptors on airway cells.

Omar S, Clarke R, Abdullah H, Brady C, Corry J, Winter H, Touzelet O, Power UF, Lundy F, McGarvey LP, Cosby SL.

PLoS One. 2017 Feb 10;12(2):e0171681. doi: 10.1371/journal.pone.0171681. eCollection 2017.

15.

In Vitro Modeling of RSV Infection and Cytopathogenesis in Well-Differentiated Human Primary Airway Epithelial Cells (WD-PAECs).

Broadbent L, Villenave R, Guo-Parke H, Douglas I, Shields MD, Power UF.

Methods Mol Biol. 2016;1442:119-39. doi: 10.1007/978-1-4939-3687-8_9.

PMID:
27464691
16.

EGFR Interacts with the Fusion Protein of Respiratory Syncytial Virus Strain 2-20 and Mediates Infection and Mucin Expression.

Currier MG, Lee S, Stobart CC, Hotard AL, Villenave R, Meng J, Pretto CD, Shields MD, Nguyen MT, Todd SO, Chi MH, Hammonds J, Krumm SA, Spearman P, Plemper RK, Sakamoto K, Peebles RS Jr, Power UF, Moore ML.

PLoS Pathog. 2016 May 6;12(5):e1005622. doi: 10.1371/journal.ppat.1005622. eCollection 2016 May.

17.

Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection.

Detalle L, Stohr T, Palomo C, Piedra PA, Gilbert BE, Mas V, Millar A, Power UF, Stortelers C, Allosery K, Melero JA, Depla E.

Antimicrob Agents Chemother. 2015 Oct 5;60(1):6-13. doi: 10.1128/AAC.01802-15. Print 2016 Jan.

18.

Induction and Antagonism of Antiviral Responses in Respiratory Syncytial Virus-Infected Pediatric Airway Epithelium.

Villenave R, Broadbent L, Douglas I, Lyons JD, Coyle PV, Teng MN, Tripp RA, Heaney LG, Shields MD, Power UF.

J Virol. 2015 Dec;89(24):12309-18. doi: 10.1128/JVI.02119-15. Epub 2015 Sep 30.

19.

Respiratory syncytial virus, an ongoing medical dilemma: an expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trials.

Broadbent L, Groves H, Shields MD, Power UF.

Influenza Other Respir Viruses. 2015 Jul;9(4):169-78. doi: 10.1111/irv.12313. Review.

20.

Dissolving microneedle delivery of nanoparticle-encapsulated antigen elicits efficient cross-priming and Th1 immune responses by murine Langerhans cells.

Zaric M, Lyubomska O, Poux C, Hanna ML, McCrudden MT, Malissen B, Ingram RJ, Power UF, Scott CJ, Donnelly RF, Kissenpfennig A.

J Invest Dermatol. 2015 Feb;135(2):425-434. doi: 10.1038/jid.2014.415. Epub 2014 Sep 22.

21.

Relative respiratory syncytial virus cytopathogenesis in upper and lower respiratory tract epithelium.

Guo-Parke H, Canning P, Douglas I, Villenave R, Heaney LG, Coyle PV, Lyons JD, Shields MD, Power UF.

Am J Respir Crit Care Med. 2013 Oct 1;188(7):842-51. doi: 10.1164/rccm.201304-0750OC.

PMID:
23952745
22.

Affinity-purified respiratory syncytial virus antibodies from intravenous immunoglobulin exert potent antibody-dependent cellular cytotoxicity.

Gupta N, LeGoff J, Chamat S, Mercier-Delarue S, Touzelet O, Power UF, Kazatchkine MD, Simon F, Lacroix-Desmazes S, Bayry J, Kaveri SV.

PLoS One. 2013 Jul 19;8(7):e69390. doi: 10.1371/journal.pone.0069390. Print 2013.

23.

Respiratory syncytial virus interaction with human airway epithelium.

Villenave R, Shields MD, Power UF.

Trends Microbiol. 2013 May;21(5):238-44. doi: 10.1016/j.tim.2013.02.004. Epub 2013 Mar 22. Review.

PMID:
23523320
24.

Skin dendritic cell targeting via microneedle arrays laden with antigen-encapsulated poly-D,L-lactide-co-glycolide nanoparticles induces efficient antitumor and antiviral immune responses.

Zaric M, Lyubomska O, Touzelet O, Poux C, Al-Zahrani S, Fay F, Wallace L, Terhorst D, Malissen B, Henri S, Power UF, Scott CJ, Donnelly RF, Kissenpfennig A.

ACS Nano. 2013 Mar 26;7(3):2042-55. doi: 10.1021/nn304235j. Epub 2013 Feb 15.

25.

The respiratory syncytial virus G protein conserved domain induces a persistent and protective antibody response in rodents.

Nguyen TN, Power UF, Robert A, Haeuw JF, Helffer K, Perez A, Asin MA, Corvaia N, Libon C.

PLoS One. 2012;7(3):e34331. doi: 10.1371/journal.pone.0034331. Epub 2012 Mar 29.

26.

In vitro modeling of respiratory syncytial virus infection of pediatric bronchial epithelium, the primary target of infection in vivo.

Villenave R, Thavagnanam S, Sarlang S, Parker J, Douglas I, Skibinski G, Heaney LG, McKaigue JP, Coyle PV, Shields MD, Power UF.

Proc Natl Acad Sci U S A. 2012 Mar 27;109(13):5040-5. doi: 10.1073/pnas.1110203109. Epub 2012 Mar 12.

27.

Differential cytopathogenesis of respiratory syncytial virus prototypic and clinical isolates in primary pediatric bronchial epithelial cells.

Villenave R, O'Donoghue D, Thavagnanam S, Touzelet O, Skibinski G, Heaney LG, McKaigue JP, Coyle PV, Shields MD, Power UF.

Virol J. 2011 Jan 27;8:43. doi: 10.1186/1743-422X-8-43.

28.

Cytopathogenesis of Sendai virus in well-differentiated primary pediatric bronchial epithelial cells.

Villenave R, Touzelet O, Thavagnanam S, Sarlang S, Parker J, Skibinski G, Heaney LG, McKaigue JP, Coyle PV, Shields MD, Power UF.

J Virol. 2010 Nov;84(22):11718-28. doi: 10.1128/JVI.00798-10. Epub 2010 Sep 1.

29.

Report of the 2nd "French Clinical Vaccinology Meeting Jean-Gerard Guillet": immunization and respiratory diseases.

Loulergue P, Burgel PR, Carrat F, Fritzell B, Guthmann JP, Locht C, Power UF, Varon E, Dusser D, Launay O.

Vaccine. 2010 Sep 14;28(40):6551-5. doi: 10.1016/j.vaccine.2010.07.038. Epub 2010 Jul 30.

PMID:
20674881
30.

De novo generation of a non-segmented negative strand RNA virus with a bicistronic gene.

Touzelet O, Loukili N, Pelet T, Fairley D, Curran J, Power UF.

Virus Res. 2009 Mar;140(1-2):40-8. doi: 10.1016/j.virusres.2008.10.019. Epub 2008 Dec 30.

PMID:
19084562
31.

Respiratory syncytial virus (RSV) vaccines--two steps back for one leap forward.

Power UF.

J Clin Virol. 2008 Jan;41(1):38-44. Review.

PMID:
18340669
32.
33.

Respiratory syncytial virus NS1 protein degrades STAT2 by using the Elongin-Cullin E3 ligase.

Elliott J, Lynch OT, Suessmuth Y, Qian P, Boyd CR, Burrows JF, Buick R, Stevenson NJ, Touzelet O, Gadina M, Power UF, Johnston JA.

J Virol. 2007 Apr;81(7):3428-36. Epub 2007 Jan 24.

34.
35.

Evaluation of BBG2Na in infant macaques: specific immune responses after vaccination and RSV challenge.

de Waal L, Power UF, Yüksel S, van Amerongen G, Nguyen TN, Niesters HG, de Swart RL, Osterhaus AD.

Vaccine. 2004 Feb 25;22(8):915-22.

PMID:
15161068
36.

Immunization of female mice with glycoconjugates protects their offspring against encapsulated bacteria.

Richter MY, Jakobsen H, Birgisdottir A, Haeuw JF, Power UF, Del Giudice G, Bartoloni A, Jonsdottir I.

Infect Immun. 2004 Jan;72(1):187-95.

37.
38.

Enhanced pulmonary immunopathology following neonatal priming with formalin-inactivated respiratory syncytial virus but not with the BBG2NA vaccine candidate.

Plotnicky H, Siegrist CA, Aubry JP, Bonnefoy JY, Corvaïa N, Nguyen TN, Power UF.

Vaccine. 2003 Jun 2;21(19-20):2651-60.

PMID:
12744902
39.

Structure-antigenicity relationship studies of the central conserved region of human respiratory syncytial virus protein G.

Sugawara M, Czaplicki J, Ferrage J, Haeuw JF, Power UF, Corvaïa N, Nguyen T, Beck A, Milton A.

J Pept Res. 2002 Nov;60(5):271-82.

PMID:
12383117
40.

Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults.

Power UF, Nguyen TN, Rietveld E, de Swart RL, Groen J, Osterhaus AD, de Groot R, Corvaia N, Beck A, Bouveret-Le-Cam N, Bonnefoy JY.

J Infect Dis. 2001 Dec 1;184(11):1456-60. Epub 2001 Nov 13.

PMID:
11709789
41.
42.

A novel bipolar mode of attachment to aluminium-containing adjuvants by BBG2Na, a recombinant subunit hRSV vaccine.

Dagouassat N, Robillard V, Haeuw JF, Plotnicky-Gilquin H, Power UF, Corvaïa N, Nguyen T, Bonnefoy JY, Beck A.

Vaccine. 2001 Jul 20;19(30):4143-52.

PMID:
11457539
43.

Identification and characterisation of multiple linear B cell protectopes in the respiratory syncytial virus G protein.

Power UF, Plotnicky-Gilquin H, Goetsch L, Champion T, Beck A, Haeuw JF, Nguyen TN, Bonnefoy JY, Corvaïa N.

Vaccine. 2001 Mar 21;19(17-19):2345-51.

PMID:
11257359
44.
45.

Influence of administration dose and route on the immunogenicity and protective efficacy of BBG2Na, a recombinant respiratory syncytial virus subunit vaccine candidate.

Goetsch L, Plotnicky-Gilquin H, Champion T, Beck A, Corvaïa N, Stâhl S, Bonnefoy JY, Nguyen TN, Power UF.

Vaccine. 2000 Jun 1;18(24):2735-42.

PMID:
10781861
46.

CD4(+) T-cell-mediated antiviral protection of the upper respiratory tract in BALB/c mice following parenteral immunization with a recombinant respiratory syncytial virus G protein fragment.

Plotnicky-Gilquin H, Robert A, Chevalet L, Haeuw JF, Beck A, Bonnefoy JY, Brandt C, Siegrist CA, Nguyen TN, Power UF.

J Virol. 2000 Apr;74(8):3455-63.

47.

Identification of multiple protective epitopes (protectopes) in the central conserved domain of a prototype human respiratory syncytial virus G protein.

Plotnicky-Gilquin H, Goetsch L, Huss T, Champion T, Beck A, Haeuw JF, Nguyen TN, Bonnefoy JY, Corvaïa N, Power UF.

J Virol. 1999 Jul;73(7):5637-45.

48.

Absence of lung immunopathology following respiratory syncytial virus (RSV) challenge in mice immunized with a recombinant RSV G protein fragment.

Plotnicky-Gilquin H, Huss T, Aubry JP, Haeuw JF, Beck A, Bonnefoy JY, Nguyen TN, Power UF.

Virology. 1999 May 25;258(1):128-40.

49.

Protective efficacy against respiratory syncytial virus following murine neonatal immunization with BBG2Na vaccine: influence of adjuvants and maternal antibodies.

Siegrist CA, Plotnicky-Gilquin H, Córdova M, Berney M, Bonnefoy JY, Nguyen TN, Lambert PH, Power UF.

J Infect Dis. 1999 Jun;179(6):1326-33.

PMID:
10228051
50.

Protective immunity against respiratory syncytial virus in early life after murine maternal or neonatal vaccination with the recombinant G fusion protein BBG2Na.

Brandt C, Power UF, Plotnicky-Gilquin H, Huss T, Nguyen T, Lambert PH, Binz H, Siegrist CA.

J Infect Dis. 1997 Oct;176(4):884-91.

PMID:
9333145

Supplemental Content

Loading ...
Support Center